Different immunoreactivity of endothelial markers in well and poorly differentiated areas of angiosarcomas

Poblet, Enrique; González-Palacios, Fernando; Jiménez, Francisco Javier

doi:10.1007/bf00196693

Cited by 48 publications

(54 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor cell lines from primitive endothelium SP Fosmire et al consistent with previously published results that suggest vWF expression may occur in later stages of differentiation and may be restricted to specific subsets of endothelial cells, [34][35][36] and with our observation that vWF expression in canine HSA appears to localize preferentially to formed vessels rather than to solid areas of malignant cells (JW, unpublished).…”

Section: Isolation Of Morphologically Homogeneous Cell Lines From Hsasupporting

confidence: 91%

Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium

Fosmire

Dickerson

Scott

et al. 2004

Laboratory Investigation

123

View full text Add to dashboard Cite

Hemangiosarcoma (HSA) is a common untreatable cancer of dogs that resembles human angiosarcoma. Detailed studies of these diseases have been historically hindered by the paucity of suitable reagents. Here, we show that expression of CD117 (c-Kit) can distinguish primitive (malignant) from mature (benign) proliferative endothelial lesions, and we describe eight independent cell lines derived from canine HSA explants. Endothelial origin was confirmed by sustained expression of surface CD105 (endoglin), CD146 (MUC18), and CD51/CD61 (a v b 3 integrin). The cell lines showed anchorage-independent growth and were motile and invasive when cultured on a basement membrane matrix. They required endothelial growth factors for growth and survival, and they could be induced to form tubular structures resembling blood vessels when cultured under low calcium conditions. The formation of vessel-like structures was blocked by nicotine, and restored by FK506, suggesting that 'nuclear factor of activated T cells' activity prevents differentiation of these cells. In summary, these cell lines represent a unique and novel resource to improve our understanding of endothelial cell biology in general and canine HSA in particular.

show abstract

Section: Isolation Of Morphologically Homogeneous Cell Lines From Hsasupporting

confidence: 91%

Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium

Fosmire

Dickerson

Scott

et al. 2004

Laboratory Investigation

123

View full text Add to dashboard Cite

show abstract

“…No loss of CD31 expression was registered in endothelial tumors, and generally all neoplastic cells within these lesions were CD31 positive, as has previously been reported by other authors. 36 CD31 has an extracellular domain that mediates endothelial cellto-cell contact and a cytoplasmic domain with potential sites for phosphorylation after cellular activation, 30 and it has been proposed to be involved in interactive events during angiogenesis. CD31 expression by tumor cells may therefore represent a selective advantage for tumor progression and invasion.…”

Section: Discussionmentioning

confidence: 99%

“…2 It is commonly used as a marker for endothelial cells in Vet Pathol 46:211-221 (2009) humans but was seldom expressed in some poorly differentiated vascular tumors. 23,36 The platelet/ endothelial cell adhesion molecule CD31 (PE-CAM-1) is a transmembrane glycoprotein, expressed in platelets, monocytes, and endothelial intercellular junctions.…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical Evaluation of Vascular Urinary Bladder Tumors from Cows with Enzootic Hematuria

Carvalho¹,

Naydan

Nunes³

et al. 2009

Veterinary Pathology

View full text Add to dashboard Cite

Abstract. Fifty-six endothelial-derived urinary bladder tumor samples collected from 26 animals with bovine enzootic hematuria were selected for immunohistochemical studies. Expression of factor VIII-related antigen (FVIIIra), CD31, muscle-specific actin, uroplakin III (UPIII), and the cell cyclerelated proteins cyclin D1 and p53 was evaluated in hemangiomas, ''hemangioendotheliomas'' (a vascular tumor that histologically is intermediate in appearance between a hemangioma and a conventional hemangiosarcoma), and hemangiosarcomas. Although CD31 expression was seen in all endothelial tumors tested, FVIIIra was not expressed in poorly differentiated endothelial tumor cells from solid areas or in 7 muscle-invasive hemangiosarcomas. Cyclin D1 overexpression was seen in 53% of hemangiomas, 82% of hemangioendotheliomas, and 95% of hemangiosarcomas. P53 immunoreactivity was only seen in muscle-invasive hemangiosarcomas. The UPIII staining pattern, normally very intense on the apical aspect and cytoplasm of superficial urothelial cells, was altered in the urothelium in an estimated 25% of hemangiomas, most hemangioendotheliomas, and most hemangiosarcomas. In conclusion, CD31 is a better marker than FVIIIra in the characterization of bovine endothelial tumors. The cell cycle regulatory pathways involving cyclin D1 and p53 seem to be impaired in endothelial urinary bladder tumors, p53 immunoreactivity positively correlating with enhanced invasion.

show abstract

“…In less differentiated areas, antibody to CD31 is more sen-sitive than anti-von Willebrand factor (20,22). CD34 antibody is less reliable in decorating cells that line lymphatic channels and therefore may not be reactive in malignant sarcomas with lymphatic lining cell differentiation (23).…”

Section: Discussionmentioning

confidence: 99%

Extracutaneous Angiosarcomas Metastatic to the Lungs: Clinical and Pathologic Features of Twenty-One Cases

et al. 2001

View full text Add to dashboard Cite

Angiosarcomas are rare malignant vascular tumors with a high rate of metastasis involving lungs (most commonly), liver, regional lymph nodes, bone, and other sites. In this study, we have reviewed the clinical presentation and histopathology of 21 cases of extracutaneous angiosarcoma metastatic to the lungs. Tumors with exclusively pleural involvement were excluded. Patients presented with dyspnea, chest pain, and/or hemoptysis lasting a few weeks to months. Radiologically, the most common finding comprised multiple peripheral lung nodules (57%), often accompanied by infiltrates. For 11 cases (52%), the primary tumor was not identified at the time of presentation. Vasoformative areas were identified in 15 cases (71%). Nine cases comprised spindle cells (43%), two contained epithelioid cells (9.5%), and 10 consisted of both spindle and epithelioid cells (48%). Nuclear pleomorphism was at least moderate in all cases. However, five tumors contained regions of minimal nuclear atypia. Hemorrhage, siderophages, and fibrosis were commonly present. Immunohistochemical staining (IHS) was performed on 14 cases. Thirteen tumors showed reactivity for vascular markers. Tumor cells reacted for Von Willebrand factor in 13 of 14 cases, and CD31 and CD34 were each positive in 2/2 cases. Two cases (of nine examined) also expressed cytokeratins. Because the tumor often first presented in the lungs before the primary sarcoma was identified, the clinical impression included both benign and malignant entities. For patients with primary cardiac tumors, symptoms referable to the primary tumor complicated the clinical presentation, and radiologic evaluation supported a clinical diagnostic impression of non-neoplastic pericarditis. Thus, angiosarcoma in the lung may elude diagnosis until histopathologic evaluation of the lung biopsy.

show abstract

Different immunoreactivity of endothelial markers in well and poorly differentiated areas of angiosarcomas

Cited by 48 publications

References 37 publications

Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium

Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium

Immunohistochemical Evaluation of Vascular Urinary Bladder Tumors from Cows with Enzootic Hematuria

Extracutaneous Angiosarcomas Metastatic to the Lungs: Clinical and Pathologic Features of Twenty-One Cases

Contact Info

Product

Resources

About